For the latest COVID-19 information for Massey, visit

News Center

Latest News

Massey researcher appointed to prestigious editorial board and recognized as a national academic inventor

Feb 01, 2018


VCU Massey Cancer Center and VCU Institute of Molecular Medicine researcher Paul B. Fisher, M.Ph., Ph.D., was recently selected to join a prestigious national organization of academic inventors and was also appointed to the editorial board of two internationally esteemed cancer research journals.

Fisher has been elected as a member of the National Academy of Inventors (NAI), a nonprofit organization that enhances the visibility of academic technology and innovation as a means to ultimately benefit society. He will be inducted among 155 renowned NAI Fellows on April 5, 2018, in Washington, D.C. This is the is highest professional accolade bestowed to academic inventors. The NAI Fellows Selection Committee chose Fisher because he “has demonstrated a highly prolific spirit of innovation in creating and facilitating outstanding inventions that have made a tangible impact on quality of life, economic development and the welfare of society.”

“I am excited and honored to be placed in the company of so many high impact scientists and entrepreneurs. In this role, I look forward to contributing to an enhanced national culture of academic invention through translation of our innovative research into patented inventions with potential for improved diagnosis and treatment of cancer, neurodegeneration and infectious diseases. Our discoveries also have significant commercial potential,” Fisher said.

NAI Fellows have produced more than 9,400 licensed technologies and companies and created more than 1.3 million jobs, with over $137 billion in revenue generated based on their discoveries.

Fisher also recently accepted an invitation to join the new editorial board of the Journal of the National Cancer Institute (JNCI) and JNCI Cancer Spectrum.

The JNCI is internationally regarded as one of the most up-to-date sources for news and information covering cancer research and treatment, and has been ranked as one of the most-cited original research cancer journals by the Institute of Scientific Information.

“It is a privilege to be recognized by this prestigious journal and invited to be a member of its illustrious editorial board. JNCI is a high impact journal that is on the cutting-edge of personalized medicine and advances in the diagnosis and treatment of cancer, areas which complement my expertise. I look forward to this challenging appointment,” Fisher said.

The three-year-appointment places Fisher among a group of experts including laboratory scientists, researchers from many institutions specializing in clinical, epidemiologic, behavioral and health outcomes and senior editors with a background in molecular and cell biology. They will participate in the peer review process to provide high quality, on-time reviews.

Fisher is a member of the Cancer Molecular Genetics research program and holds the Thelma Newmeyer Corman Endowed Chair in Cancer Research at Massey. He is also chair and professor of the Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine at the VCU School of Medicine.

His research has resulted in an enhanced understanding of cancer progression and metastasis and has culminated in the development of viruses that selectively kill cancer cells, informed a more effective delivery of therapeutic viruses and proteins in vivo in pre-clinical animal cancer models and led to innovative approaches for non-invasively imaging metastases in vivo.

Fisher has over 55 issued U.S. patents in addition to multiple foreign patents. He has nearly 600 primary and review papers. He co-founded Cancer Targeting Systems, Inc., a Virginia- and Maryland-based company focused on imaging and therapy for metastatic cancer. He also co-founded InVaMet Therapeutics, focusing on small molecule anti-invasive and anti-metastatic drugs, and Interleukin Combinatorial Therapeutics, which develops novel cytokine-based therapies for cancer.

Written by: Blake Belden

Related News

Center News & Funding

Massey physicians named Richmond’s “Top Docs”

Get access to new, innovative care

Get access to new, innovative care

Treatments in clinical trials may be more effective or have fewer side effects than the treatments that are currently available. With more than 200 studies for multiple types of cancers and cancer prevention, Massey supports a wide array of clinical trials.

Search clinical trials
Find a provider

Find a provider

Massey supports hundreds of top cancer specialists serving the needs of our patients. Massey’s medical team provides a wealth of expertise in cancer diagnosis, treatment, prevention and symptom management.

Find a provider